Pfizer Inc. (NYSE:PFE) Director Acquires $28,240.00 in Stock

by · The Cerbat Gem

Pfizer Inc. (NYSE:PFE – Get Free Report) Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Pfizer Trading Down 0.8 %

NYSE:PFE traded down $0.23 on Thursday, reaching $28.29. 37,873,916 shares of the stock traded hands, compared to its average volume of 37,217,828. The firm has a market capitalization of $160.31 billion, a price-to-earnings ratio of 38.38, a price-to-earnings-growth ratio of 0.99 and a beta of 0.67. The company’s 50 day moving average is $29.06 and its 200-day moving average is $28.56. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54.

Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.17) EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.67 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.94%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is presently 227.03%.

Institutional Trading of Pfizer

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PFE. Cornerstone Wealth Management LLC grew its position in shares of Pfizer by 19.4% during the 1st quarter. Cornerstone Wealth Management LLC now owns 63,545 shares of the biopharmaceutical company’s stock worth $1,763,000 after buying an additional 10,314 shares during the period. First Trust Direct Indexing L.P. grew its position in shares of Pfizer by 45.0% during the 1st quarter. First Trust Direct Indexing L.P. now owns 51,735 shares of the biopharmaceutical company’s stock worth $1,436,000 after buying an additional 16,060 shares during the period. Accel Wealth Management acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $205,000. American National Bank & Trust Co. VA acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $285,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $315,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on PFE. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. UBS Group upped their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Barclays upped their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Read Our Latest Report on Pfizer

Pfizer Company Profile

(Get Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles